A RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF PT010 RELATIVE TO PT003 AND PT009 ON COPD EXACERBATIONS OVER A 52-WEEK TREATMENT PERIOD IN SUBJECTS WITH MODERATE TO VERY SEVERE COPD

Pearl Therapeutics Inc.,0 个研究点目标入组 191 人开始时间: 2016年7月4日最近更新: 2023年9月4日

适应症

试验速览

阶段: 未知
状态: 已完成
发起方: Pearl Therapeutics Inc.,
入组人数: 191

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 40 至 80（—）
性别: All

入选标准

•1. Give their signed written informed consent to participate.
•2. Are at least 40 years of age and no older than 80 years at Visit 1.
•3. A female is eligible to enter and participate in the study if she is of:
•a. Non-childbearing potential (i.e., physiologically incapable of becoming pregnant, including any female who is 2 years post-menopausal)
•b. Childbearing potential, has a negative serum pregnancy test at Visit 1, and agrees to one of the following acceptable contraceptive methods used consistently and correctly as outlined below (i.e., in accordance with the approved product label and the instructions of the physician for the duration of the study – from Visit 1 (Screening) until 14 days after the Final Visit):
•− Complete abstinence from intercourse (when it is preferred and usual lifestyle of the patient); or
•− Implants of levonorgestrel inserted for at least 1 month prior to the study drug administration but not beyond the third successive year following insertion; or
•− Injectable progestogen administered for at least 1 month prior to study drug administration; or
•− Oral contraceptive (combined or progestogen only) administered for at least one monthly cycle prior to study drug administration; or
•− Double barrier method: condom or occlusive cap (diaphragm or cervical/vault caps) plus spermicidal agent (foam/gel/film/cream/suppository); or
•− An intrauterine device, inserted by a qualified physician, with published data showing that the highest expected failure rate is less than 1% per year; or
•− Estrogenic vaginal ring; or
•− Percutaneous contraceptive patches.
•Note: The acceptable contraceptive methods listed above are subject to locally approved contraceptive methods.
•4. COPD Diagnosis: Subjects with an established clinical history of COPD as defined by the American Thoracic Society (ATS)/European Respiratory Society (ERS) [Celli, 2004] or by locally applicable guidelines, e.g., JRS Guidelines [JRS, 2013] characterized by:
•− Progressive airflow limitation associated with an abnormal inflammatory response of the lungs to noxious particles or gases, primarily caused by cigarette smoking.
•5. Tobacco Use: Current or former smokers with a history of at least 10 pack-years of cigarette smoking. [Number of pack-years = (number of cigarettes per day / 20) x number of years smoked (e.g., 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years represent 10 pack-years)].
•6. COPD Severity: Subjects with an established clinical history of COPD and severity defined as:
•− At Visit 1, FEV1/FVC ratio must be <0.70 and FEV1 must be <65% predicted normal value calculated using NHANES III reference equations (Or reference norms applicable to other regions, e.g., for Japan, use JRS reference equations; [JRS, 2013]).
•− At Visit 2, post-bronchodilator FEV1/FVC ratio of <0.70 and post-bronchodilator FEV1 must be ≥25% to <65% predicted normal value, calculated using NHANES III reference equations (Or reference norms applicable to other regions, e.g., for Japan, use JRS reference equations [JRS, 2013]).
•− At Visit 4, the average of the -60 min and -30 min pre-dose FEV1 assessments must be <65% predicted normal value, calculated using NHANES III reference equations (Or reference norms applicable to other regions, e.g., for Japan, use JRS reference equations [JRS, 2013]).

排除标准

•1. Significant diseases or conditions other than COPD, which, in the opinion of the Investigator, may put the subject at risk because of participation in the study or may influence either the results of the study or the subject’s ability to participate in the study.
•2. Women who are pregnant or lactating, or are planning to become pregnant during the course of the study, or women of childbearing potential who are not using an acceptable method of contraception.
•3. Respiratory:
•a. Asthma: Subjects, who in the opinion of the Investigator, have a current diagnosis of asthma.
•b. Alpha-1 Antitrypsin Deficiency: Subjects who have alpha-1 antitrypsin deficiency as the cause of COPD.
•c. Other Respiratory Disorders: Subjects who have other active pulmonary disease such as active tuberculosis, lung cancer, significant bronchiectasis (high resolution CT evidence of bronchiectasis that causes repeated acute exacerbations), sarcoidosis, idiopathic interstitial pulmonary fibrosis, primary pulmonary hypertension, or uncontrolled sleep apnea (i.e., in the opinion of the Investigator severity of the disorder would impact the conduct of the study). Note: Allergic rhinitis is not exclusionary.
•d. Lung Volume Reduction: Subjects who have undergone lung volume reduction surgery, lobectomy or bronchoscopic lung volume reduction (endobronchial blockers, airway bypass, endobronchial valves, thermal vapor ablation, biological sealants, and airway implants) within 1 year of Visit 1.
•e. Hospitalization: Subjects who have been hospitalized due to poorly controlled COPD within 3 months prior to Visit 1 (Screening) or during the Screening Period (Visit 1 to Visit 4).
•f. Poorly Controlled COPD: Subjects who have poorly controlled COPD, defined as acute worsening of COPD that requires treatment with oral corticosteroids or antibiotics within 6 weeks prior to Visit 1 (Screening) or during the Screening Period (Visit 1 to Visit 4).
•Note: Subjects who are steroid dependent and maintained on an equivalent of 5 mg prednisone per day or 10 mg every other day for at least 3 months prior to Visit 1 are eligible for enrollment providing the dose of oral steroids remains stable during the Screening Period Visit 1 through Visit 4.
•g. Lower Respiratory Tract Infection: Subjects who had lower respiratory tract infections that required antibiotics within 6 weeks prior to Visit 1 (Screening) or during the Screening Period (Visit 1 to Visit 4).
•h. Other Respiratory tract infections that have not resolved at least 7 days prior to Screening
•The other criteria for exclusion are described in the protocol

研究者

发起方

Pearl Therapeutics Inc.,

相似试验

进行中（未招募）

不适用

A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO DEMONSTRATE THE EFFICACY AND SAFETY OF ADAPALENE/BENZOYL PEROXIDE TOPICAL GEL COMPARED WITH ADAPALENE TOPICAL GEL, 0.1%; BENZOYL PEROXIDE TOPICAL GEL, 2.5% AND TOPICAL GEL VEHICLE IN SUBJECTS WITH ACNE VULGARIS

EUCTR2006-004215-21-DEGalderma Research & Development Inc.1,656

进行中（未招募）

不适用

EUCTR2006-004215-21-HUGalderma Research & Development Inc.1,656

进行中（未招募）

1 期

A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF TWO LENALIDOMIDE DOSE REGIMENS IN SUBJECTS WITH RELAPSED OR REFRACTORY B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA

EUCTR2006-004469-32-FRCelgene Corporation340

已完成

不适用

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, STUDY OF 12 WEEKS OF DURATION TO EVALUATE THE EFFICACY AND SAFETY OF MK-0524B (IN CODMINISTRATION OF DOSES OF MK-0524A AND SIMVASTATIN TABLETS) AGAINST ATORVASTATIN IN PATIENTS WITH HYPERLIPIDEMIA MIXED

PER-070-08MERCK SHARP & DOHME PERU S.R.L.,9

进行中（未招募）

1 期

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP STUDY, COMPARING THE EFFICACY AND TOLERABILITY OF ZIPRASIDONE (ZELDOX®, GEODON®) VS OLANZAPINE (ZYPREXA®) IN THE TREATMENT AND MAINTENANCE OF RESPONSE IN PATIENTS WITH ACUTE MANIA - ZOOM STUDY: ZIPRASIDONE AND OLANZAPINE’S OUTCOMES IN MANIAMedDRA version: 8.1Level: LLTClassification code 10004939Bipolar I Disorder

EUCTR2005-004391-21-FRPfizer Ltd - Sandwich Laboratories352